5% partial response, but the observed median survival time of 9.2 months, with a median time to progression of 5.5 months60 TGX-221 was classified as a signal of m Resembled clinical benefit, as the expected mean of these patients survive gt betr 6 months. Interestingly, patients had to activation of the Ras / MAPK by positive F ERK staining for p evaluated more time to progression. Therefore, a phase III clinical study was performed in a total of 602 patients with advanced HCC. The study was survival at interim analysis because of the advantages favoring sorafenib versus placebo 7 is stopped. Based on 321 Todesf Ll the hazard ratio for sorafenib / placebo 0.69, representing a 31% reduction in risk of death with a median survival in the sorafenib arm, 10.6 months versus 7.9 months for the placebo group .
In addition, sorafenib showed significant benefit AT9283 Bcr-Abl inhibitor in terms of time to radiographic progression through independent Independent verification with a median TTP of 5.5 months for sorafenib and 2.8 months with placebo assessed. Overall, the h Ufigsten side effects are diarrhea, fatigue, weight loss and skin reactions food source. Grade 3/4 adverse effects such as diarrhea and hand-foot skin reactions were h More frequently with sorafenib. The discontinuation of the drug due to adverse events of sorafenib was 15%, but drug-related adverse events were manageable and not as Todesf Ll associated with toxicity Been described t. The St strength The evidence provided by this test is the hour HIGHEST level by the NCI classification61, and the extent of their effectiveness in terms of survival compared with other established molecular targeted therapies.
In the SHARP trial, the hazard ratio for death of 0.69. The absolute translation in the months of life gained for such HR h Depends on the median survival time of the target group. In this test, the net survival advantage of approximately 3 months. If the size S the difference was maintained with an HR of 0.69 in patients with intermediate stage, for example, k nnte Significant improvement in the survival rate for six months. Table 3 shows that the effect of sorafenib in comparison with other established treatments such as trastuzumab in breast, colon, or Erlotinib Bevacizumab cancer8 cancer.9 in non-small cell lung cancer.10, where the lower risk of death approximately 25 to 35%. Are the consequences of the test, there are three reasons.
First, sorafenib has become the standard of care for patients with advanced HCC and also for those who have progressed after loco regional therapies. This explanation Tion was held by a panel of experts in trial design in HCC, which was approved by the AASLD 53, and modifies the schedule accepted treatment described in Figure 5. Therefore, sorafenib was found that the arm for the design of future studies in this regard. Second, the evidence from the study that targeted therapies are active in this otherwise chemo-resistant tumor. Really You open a path for combination therapies blocking several routes. Closing Lich he Opened the positive outcome in advanced F Fill the M Possibility that this compound in the adjuvant setting, ie to test after curative potential, and the area is an unmet need in the treatment of liver cancer. Bevacizumab is a humanized monoclonal antibody Body against VEGF for the treatment of breast cancer and liver metastases of colorectal cancer admitted directed. The mechanism